Balchem (BCPC) Cash & Equivalents (2009 - 2026)

Balchem has reported Cash & Equivalents for 18 years, with the latest figure at $63.2 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $63.2 million, down 3.44% year-over-year; the trailing twelve-month figure through Jun 2026 was $63.2 million (down 3.44% YoY), and the FY2025 annual result was $74.6 million, up 50.6% from the prior year.
• Cash & Equivalents fell to $63.2 million in Q2 2026, from $72.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $77.0 million in Q3 2023 and troughed at $49.5 million in Q4 2024.
• A 5-year average of $65.0 million and a median of $64.8 million in 2022 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents tumbled 37.24%; it then jumped 50.6% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $66.6 million in 2022, then retreated by 3.17% to $64.4 million in 2023, then fell by 23.17% to $49.5 million in 2024, then jumped by 50.6% to $74.6 million in 2025, then retreated by 15.28% to $63.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $63.2 million in Q2 2026, $72.9 million in Q1 2026, and $74.6 million in Q4 2025.